Inhibrx Biosciences, Inc.
INBX
$113.07
$0.210.19%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | -- | 1.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | -- | 1.30M |
| Cost of Revenue | 23.90M | 25.22M | 25.35M | 28.54M | 22.27M |
| Gross Profit | -23.90M | -25.22M | -25.35M | -28.54M | -20.97M |
| SG&A Expenses | 8.25M | 5.71M | 5.57M | 5.28M | 6.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.15M | 30.93M | 30.92M | 33.81M | 28.69M |
| Operating Income | -32.15M | -30.93M | -30.92M | -33.81M | -27.39M |
| Income Before Tax | -36.65M | -33.44M | -32.83M | -35.26M | -28.65M |
| Income Tax Expenses | 3.00K | -- | 0.00 | -- | 2.00K |
| Earnings from Continuing Operations | -36.65M | -33.44M | -32.83M | -35.26M | -28.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.65M | -33.44M | -32.83M | -35.26M | -28.65M |
| EBIT | -32.15M | -30.93M | -30.92M | -33.81M | -27.39M |
| EBITDA | -31.63M | -30.39M | -30.36M | -33.23M | -26.73M |
| EPS Basic | -2.34 | -2.15 | -2.11 | -2.28 | -1.85 |
| Normalized Basic EPS | -1.46 | -1.34 | -1.32 | -1.42 | -1.16 |
| EPS Diluted | -2.34 | -2.15 | -2.11 | -2.28 | -1.85 |
| Normalized Diluted EPS | -1.46 | -1.34 | -1.32 | -1.42 | -1.16 |
| Average Basic Shares Outstanding | 15.67M | 15.59M | 15.53M | 15.48M | 15.47M |
| Average Diluted Shares Outstanding | 15.67M | 15.59M | 15.53M | 15.48M | 15.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |